Related Experiment Video

Updated: Jun 5, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Non-genotoxic p53-activators and their significance as antitumor therapy of future

S K Nayak1, P S Panesar, H Kumar

  • 1Department of Chemistry, Sant Longowal Institute of Engineering & Technology (Deemed University), Longowal, Sangrur 148106, India. hk67@rediffmail.com

Current Medicinal Chemistry
|January 25, 2011
PubMed

Insights

The tumor suppressor protein p53 is crucial for preventing cancer but is often inactivated in malignancies. This review explores non-genotoxic activators of p53 as a promising anticancer therapy with fewer side effects than traditional treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The tumor suppressor protein p53 plays a vital role in cell cycle regulation, apoptosis, DNA repair, and senescence.
  • Inactivation or downregulation of p53 is observed in various cancers, including Li-Fraumeni syndrome, hepatocellular carcinoma, breast, cervical, and acute myeloid leukemia.
  • p53 is a significant target for developing novel anticancer agents.

Purpose of the Study:

  • To review mechanisms of p53 inactivation in cancer.
  • To discuss recently developed non-genotoxic p53 activators and their therapeutic potential in neoplastic disorders.
  • To summarize the advantages of non-genotoxic p53-activating agents over conventional therapies and outline future challenges.

Main Methods:

  • Literature review of p53 inactivation mechanisms.
  • Analysis of recently developed non-genotoxic p53 activators.
  • Comparative assessment of non-genotoxic versus conventional anticancer therapies.

Main Results:

  • Conventional therapies often rely on genotoxic agents that stabilize wild-type p53 (wt-p53) via DNA damage, leading to severe side effects.
  • Emerging non-genotoxic approaches show promise for reactivating p53 without causing DNA damage.
  • Inhibitors of p53 have been identified for preventing normal cell death in various diseases.

Conclusions:

  • Non-genotoxic p53 activators offer a potentially safer and more effective alternative to conventional genotoxic anticancer therapies.
  • Understanding p53 inactivation mechanisms is key to developing targeted therapies.
  • Further research is needed to overcome challenges in p53-based cancer therapy.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...